Summary: Skye Bioscience Inc, a clinical-stage biopharmaceutical company, reported its second-quarter results, emphasizing the upcoming phase 2 trial of nimacimab, a treatment for obesity that will also explore the impact of weight loss on sleep quality using Beacon Biosignal’s … [Read more...]
Eli Lilly’s Weight Loss Drug Zepbound Cuts Sleep Apnea Severity
Summary: Eli Lilly announced that its weight-loss drug Zepbound (tirzepatide) reduced the severity of obstructive sleep apnea (OSA) by up to 63% in adults with obesity in two phase 3 trials. The drug improved sleep apnea symptoms in patients using and not using PAP therapy. Based … [Read more...]